8 completed, 5 terminated, 4 active not recruiting, 1 not yet recruiting. 20 Phase 2, 4 Phase 1, 2 Phase 3.
Follow XRP6258: new trials by email Literature Review of XRP6258 trials Research Report on XRP6258
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Use of High Dose Testosterone Followed by Darolutamide Compared to the Usual Care for Patients With Metastatic Prostate Cancer Abiraterone Acetate, Biospecimen Collection, Bone Scan - Metastatic Castration-Resistant Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8 | Phase 2 / Phase 3 | Not yet recruiting | ECOG-ACRIN Cancer Research Group | 432 | 2027-01-06 | 2026-10-01 |
| Phase II Study of the Use of Neoadjuvant Cabazitaxel With Hormonal Treatment in Patients Operable Prostate Cancer, Assess the Efficacy and Toxicity of Cabazitaxel, and Explore Potential Predictive and Prognostic Markers of Clinical Outcome Cabazitaxel - Prostate Cancer | Phase 2 | Unknown | The Clatterbridge Cancer Centre NHS Foundation Trust | 120 | 2021-01-15 | 2021-01-05 |
| Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer Cabazitaxel, Carboplatin, Cetrelimab - Aggressive Variant Prostate Carcinoma, Castration-Resistant Prostate Carcinoma | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 120 | 2020-12-29 | 2026-09-09 |
| Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer Previously Treated With Docetaxel Abiraterone Acetate, Androgen deprivation therapy, Cabazitaxel - Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma | Phase 2 | Active not recruiting | ECOG-ACRIN Cancer Research Group | 223 | 2018-04-26 | 2026-10-06 |
| Cabazitaxel and Prednisone in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Cabazitaxel, Prednisone - Hormone-Resistant Prostate Cancer, Stage IV Prostate Adenocarcinoma | Phase 2 | Terminated | University of California, Davis | 2 | 2017-12-20 | 2021-01-25 |
| Abiraterone Acetate, Prednisone, and Apalutamide With or Without Ipilimumab or Cabazitaxel and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer Abiraterone Acetate, Apalutamide, Cabazitaxel - Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 196 | 2016-05-18 | 2026-09-14 |
| Enzalutamide and Cabazitaxel in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer Cabazitaxel, Enzalutamide, Laboratory Biomarker Analysis - Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma | Phase 1 / Phase 2 | Active not recruiting | OHSU Knight Cancer Institute | 37 | 2015-08-13 | 2026-09-15 |
| A Study of Cabazitaxel for Patients With Breast or Lung Cancer and Recurrent or Progressive Brain Metastases - Cabazitaxel for Brain Metastases (CaBaMet) Cabazitaxel - Breast Cancer, Lung Cancer | Phase 2 | Terminated | AIO-Studien-gGmbH | 8 | 2015-08-01 | 2018-01-23 |
| Cabazitaxel Plus Lapatinib as Therapy for HER2-Positive Metastatic Breast Cancer Patients With Intracranial Metastases cabazitaxel, lapatinib - Metastatic Breast Cancer With Intracranial Metastases | Phase 2 | Terminated | SCRI Development Innovations, LLC | 11 | 2014-05-01 | 2017-07-02 |
| Early Switch From First-Line Docetaxel/Prednisone to Cabazitaxel/Prednisone and the Opposite Sequence, Exploring Molecular Markers in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC) DOCETAXEL (XRP6976), CABAZITAXEL (XRP6258), Prednisone - Prostate Cancer Metastatic | Phase 2 | Completed | Sanofi | 63 | 2013-03-01 | 2017-11-20 |
| Cabazitaxel in Men 75 Years of Age or Older With Castration-Resistant Prostate Cancer Cabazitaxel, Prednisone, Granulocyte colony-stimulating factor (G-CSF) - Castrate-resistant Metastatic Prostate Cancer | Phase 2 | Withdrawn | Case Comprehensive Cancer Center | 2013-02-01 | 2013-10-16 | |
| Safety and Efficacy of Cabazitaxel in Pediatric Patients With Refractory Solid Tumors Including Central Nervous System Tumors Cabazitaxel (XRP6258) - Malignant Solid Tumor - Malignant Nervous System Neoplasm | Phase 1 / Phase 2 | Completed | Sanofi | 39 | 2013-02-01 | 2016-08-12 |
| Treatment of Locally Advanced or Metastatic Transitional Cell Carcinoma With Cabazitaxel Cabazitaxel, Best Supportive Care - Transitional Cell Carcinoma | Phase 2 / Phase 3 | Completed | Dr Anjali Zarkar | 20 | 2013-01-01 | 2018-12-04 |
| Study of Cabazitaxel in Patients With Metastatic Breast Cancer Previously Treated With Taxanes Cabazitaxel - Breast Cancer | Phase 2 | Completed | Hellenic Cooperative Oncology Group | 84 | 2012-09-01 | 2017-08-01 |
| Continued Treatment With Docetaxel Versus Switch to Cabazitaxel After Minor Prostate Specific Antigen Response to Docetaxel in Patients With Castration-Resistant Metastatic Prostate Cancer CABAZITAXEL (XRP6258), DOCETAXEL (XRP6976) - Prostatic Neoplasms | Phase 2 | Completed | Sanofi | 2 | 2012-08-01 | 2013-12-24 |
| Cabazitaxel With or Without Carboplatin in Treating Patients With Previously Treated Metastatic Castration-Resistant Prostate Cancer Cabazitaxel, Carboplatin, Laboratory Biomarker Analysis - Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma | Phase 1 / Phase 2 | Completed | M.D. Anderson Cancer Center | 170 | 2012-07-11 | 2021-07-30 |
| Cabazitaxel Plus Prednisone With Octreotide For Castration-Resistant Prostate Cancer (CRPC) Previously Treated With Docetaxel cabazitaxel, prednisone, octreotide pamoate - Diarrhea, Hormone-resistant Prostate Cancer | Phase 2 | Terminated | University of Southern California | 9 | 2012-07-01 | 2014-11-24 |
| Cabazitaxel Compared to Topotecan for the Treatment of Small Cell Lung Cancer Cabazitaxel, Topotecan - Small Cell Lung Cancer | Phase 2 | Completed | Sanofi | 179 | 2012-03-01 | 2015-04-13 |
| Cabazitaxel in Patients With Urothelial Carcinoma Who Have Disease Progression Following Platinum-Based Chemotherapy Cabazitaxel, Neulasta, CT Scan - Urothelial Carcinoma | Phase 2 | Completed | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 14 | 2012-02-16 | 2025-05-04 |
| Dose-Escalation, Safety, Pharmacokinetics Study of Cabazitaxel With Gemcitabine In Patients With Solid Tumor cabazitaxel, gemcitabine - Neoplasms, Malignant | Phase 1 / Phase 2 | Terminated | Sanofi | 19 | 2009-11-01 | 2013-09-11 |
Prostatic Neoplasms (9) · Breast Neoplasms (2) · Carcinoma, Transitional Cell (2) · Neoplasms (2) · Brain Neoplasms (1) · Diarrhea (1) · Lung Neoplasms (1) · Lymphadenopathy (1) · Neoplasm Metastasis (1) · Recurrence (1) · Small Cell Lung Carcinoma (1) · Urinary Bladder Neoplasms (1)
Sanofi (5) · M.D. Anderson Cancer Center (3) · ECOG-ACRIN Cancer Research Group (2) · AIO-Studien-gGmbH (1) · Case Comprehensive Cancer Center (1) · Dr Anjali Zarkar (1) · Hellenic Cooperative Oncology Group (1) · OHSU Knight Cancer Institute (1) · SCRI Development Innovations, LLC (1) · Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University (1) · The Clatterbridge Cancer Centre NHS Foundation Trust (1) · University of California, Davis (1) · University of Southern California (1)
United States (13) · Canada (3) · Brazil (2) · Germany (2) · Greece (2) · Chile (1) · France (1) · Hungary (1) · Italy (1) · Norway (1) · Poland (1) · Puerto Rico (1) · Romania (1) · Russia (1) · South Korea (1)
Ana Aparicio (2) · Angelos Koutras, MD (1) · Anjali Zarkar (1) · Christopher Evans (1) · Christos Kyriakopoulos (1) · Dale Shepard, Md, PhD (1) · Denise A. Yardley, MD (1) · Frank Kullmann, Prof. Dr. (1) · Jacek Pinski (1) · Jean Hoffman-Censits, MD (1) · Julie N Graff (1) · Michael Schweizer (1) · Paul Corn (1)
PMID 26200278, PMID 28632486, PMID 29678476, PMID 30301829, PMID 30537991, PMID 31515154
U10CA180820 (2), P30CA016672 (1)